SCHEMBL10003130

SCHEMBL10003130

Cc1nc2c(nc1-c1ccccc1)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 2/20 0.38
▸ MDM2 Q00987 2/20 0.38
▸ MCL1 Q07820 2/20 0.38
▸ ADORA3 P0DMS8 2/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ GRIA2 P42262 1/20 0.34
▸ GRIA4 P48058 1/20 0.34
▸ PDE1A P54750 1/20 0.34
▸ PDE1B Q01064 1/20 0.34
▸ PDE1C Q14123 1/20 0.34
▸ TP53 P04637 2/20 0.34
▸ PTGER1 P34995 1/20 0.34
▸ P2RX3 P56373 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003360 0.88 CYP1A2 (0.47) ADORA3MEN1KMT2AKDM4EALDH1A1
SCHEMBL10003011 0.80 HCRTR1 (0.36) ADORA3MEN1KMT2AGRIA2GRIA4
SCHEMBL10003392 0.78 PPARG (0.33) BCL2MDM2MCL1ADORA3MEN1
SCHEMBL10002958 0.78 SMO (0.40) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL10003857 0.76 MCL1 (0.36) BCL2MDM2MCL1ADORA3MEN1
SCHEMBL10004654 0.76 GRIA2 (0.37) BCL2MDM2MCL1ADORA3GRIA2
SCHEMBL10003648 0.76 GABRA2 (0.39) BCL2MDM2MCL1KDM4EALDH1A1
SCHEMBL10003237 0.72 RAB9A (0.51) ADORA3MEN1KMT2AKDM4EALDH1A1
SCHEMBL10004729 0.71 HKDC1 (0.53) ALDH1A1SMN1; SMN2TSHR
SCHEMBL10004308 0.70 CYP1A2 (0.44) ADORA3MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH BCL2 1172/4885MDM2 1398/4885MCL1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback